State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3

Cited by (494)

Items 301–400 of 494

1. Multimorbidity clusters: translating research evidence into actionable interventions
   Alessandra Marengoni, Federico Triolo, Alberto Zucchelli · 2025 · European Geriatric Medicine
2. The impact of hypoglycemia on healthcare costs: a modeling study from Chile
   Carlos Balmaceda, Manuel Espinoza, Báltica Cabieses V, Nazareth Espinoza · 2020 · Expert Review of Pharmacoeconomics & Outcomes Research
3. Health economic evaluations of medical tests: Translating laboratory information into value – A case study example
   Paul Jülicher, Maurice O’Kane, Christopher P. Price, Robert H. Christenson, Andrew St John · 2021 · Annals of Clinical Biochemistry International Journal of Laboratory Medicine
4. Cost-Effectiveness of Hypochlorous Acid Preserved Wound Cleanser versus Saline Irrigation in Conjunction with Ultrasonic Debridement for Complex Wounds
   Peter J. Mallow, John M. Hiebert, Martin C. Robson · 2021 · Journal of health economics and outcomes research
5. A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America
   Aaron N. Winn, Anirban Basu, Scott David Ramsey · 2023 · PharmacoEconomics - Open
6. Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
   N Xander, W. Edward Fiets, Carin A. Uyl‐de Groot · 2023 · Frontiers in Oncology
7. Identifying the Optimum Strategy for Identifying Adults and Children With Celiac Disease: A Cost-Effectiveness and Value of Information Analysis
   Edna Keeney, Martha Maria Christine Elwenspoek, Joni Jackson, Cristina Roadevin, Hayley E. Jones, Rachel O’Donnell, Athena Louise Sheppard, Sarah Dawson, Deborah Lane, Jo Stubbs et al. · 2023 · Value in Health
8. Quantifying the cost savings and health impacts of improving colonoscopy quality: an economic evaluation
   Stephen McCarthy, Matthew D. Rutter, Peter J McMeekin, Jamie Catlow, Linda Sharp, Matthew Brookes, Roland Valori, Rashmi Bhardwaj-Gosling, Tom Lee, Richard McNally et al. · 2024 · BMJ Quality & Safety
9. Exploring a Markov Model Framework to Quantify Societal Preferences, Concerning Age and Severity of Disease, for Health Resource Allocation
   Zsombor Zrubka, Zoltán Hermann, Márta Péntek · 2023 · Acta Polytechnica Hungarica
10. Pain medication tapering for patients with Persistent Spinal Pain Syndrome Type II, treated with Spinal Cord Stimulation: A RCT–study protocol of the PIANISSIMO study
    Maarten Moens, Cleo Lina Crunelle, Koen D. Putman, Elke Wuyts, Frenn Bultinck, Hubert Van Puyenbroeck, Lisa Goudman · 2024 · PLoS ONE
11. Efficient use of mepolizumab in children: An analysis of the economically justifiable price in Colombia
    Jefferson Antonio Buendía, Andrés Felipe Zuluaga · 2024 · Pediatric Pulmonology
12. Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis
    Nataniel Hernan Lester-Coll, Janie M. Lee, Keerthi Gogineni · 2015 · Breast Cancer Research and Treatment
13. Methods to construct a step-by-step beginner’s guide to decision analytic cost-effectiveness modeling
    Tamlyn Anne Rautenberg, Claire T. Hulme, Richard P. Edlin · 2016 · ClinicoEconomics and Outcomes Research
14. Cost–utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effort
    Rebecca Forster, A. Hall Ratcliffe, Megan Lewis · 2018 · The European Journal of Health Economics
15. Leveraging DICE (Discretely-Integrated Condition Event) Simulation to Simplify the Design and Implementation of Hybrid Models
    J. Jaime, Ross Maconachie, Michael Woods · 2020 · Value in Health
16. Choice between implants in knee replacement: protocol for a Bayesian network meta-analysis, analysis of joint registries and economic decision model to determine the effectiveness and cost-effectiveness of knee implants for NHS patients—The KNee Implant Prostheses Study (KNIPS)
    Elsa M R Marques, Jane A Dennis, Andrew David Beswick, Julian P. T. Higgins, Howard H. Z. Thom, Nicky J. Welton, Amanda Burston, Linda P. Hunt, Michael Richard Whitehouse, Ashley William Blom · 2021 · BMJ Open
17. Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK – Results from micro-simulation model
    Jorne Lionel Biccler, Kaatje Bollaerts, Pareen Vora · 2021 · IJC Heart & Vasculature
18. Estimating transition probabilities between health states using US longitudinal survey data
    Juergen Jung · 2022 · Empirical Economics
19. The NightLife study — the clinical and cost-effectiveness of thrice-weekly, extended, in-centre nocturnal haemodialysis versus daytime haemodialysis using a mixed methods approach: study protocol for a randomised controlled trial
    Katherine Leigh Hull, Kate Bramham, Cassandra L. Brookes, Victoria Cluley, Carmel Conefrey, Nicola J. Cooper, Helen Eborall, James Fotheringham, Matthew P. M. Graham-Brown, Laura J. Gray et al. · 2023 · Trials
20. Evaluating the health and health economic impact of the COVID-19 pandemic on delayed cancer care in Belgium: A Markov model study protocol
    Yasmine Khan, Nick Verhaeghe, Robby De Pauw, Brecht Devleesschauwer, Sylvie Gadeyne, Vanessa Gorasso, Yolande N. Lievens, Niko Speybroek, Nancy Van Damme, Miet Vandemaele et al. · 2023 · PLoS ONE
21. Estimating Transition Probabilities for Modeling Major Depression in Adolescents by Sex and Race or Ethnicity Combinations in the USA
    Tran T. Doan, David W. Hutton, Davene R. Wright, Lisa A. Prosser · 2024 · Applied Health Economics and Health Policy
22. The conceptualisation of cardiometabolic disease policy model in the UK
    Septiara Putri, Giorgio Ciminata, Jim Lewsey, Bhautesh Jani, Nicola McMeekin, Claudia Geue · 2024 · BMC Health Services Research
23. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
    Vimalanand S. Prabhu, Jason Foo, Harblas Ahir · 2017 · Journal of Medical Economics
24. Critical assessment of uncertainty in economic evaluations on influenza vaccines for the elderly population in Spain
    Raúl Ortíz de Lejarazu, Javier Díez‐Domingo, Ángel Gil de Miguel, Federico Martinón‐Torres, Esther Redondo Margüello, Juan Luis López-Belmonte Claver, Paloma Isabel Palomo-Jimenez, J. Manel Farré Avellà, José María Abellán Perpiñán · 2025 · BMC Infectious Diseases
25. Impact of Limited Sample Size and Follow-up on Partitioned Survival and Multistate Modeling-Based Health Economic Models: A Simulation Study
    Jaclyn Marie Beca, Kelvin Chan, David M. J. Naimark · 2025 · Medical Decision Making
26. Critical Analysis of Markov Modeling for the Economic Evaluation of Obesity Interventions: A Systematic Review
    Qiucen Lin, Carolina Oi Lam Ung, Yunfeng Lai, Hao Hu, Mihajlo B Jakovljevic · 2025 · Risk Management and Healthcare Policy
27. Beyond the States: Developing a Discrete Event Simulation Model Using R
    Ziyi Lin, Andrew Briggs · 2025 · PharmacoEconomics
28. Using Microsimulation Modeling to Inform EHE Implementation Strategies in Los Angeles County
    Emmanuel Fulgence Drabo, Corrina Moucheraud, Anthony Nguyen, Wendy Garland, Ian W. Holloway, Arleen A. Leibowitz, Sze‐chuan Suen · 2022 · JAIDS Journal of Acquired Immune Deficiency Syndromes
29. A long-term cost-effectiveness analysis of cardiac resynchronisation therapy with or without defibrillator based on health claims data
    Moritz Hadwiger, Laura Schumann, Nora Eisemann, Nikolaos Dagres, Gerhard Hindricks, Janina Haug, Michael S. Wolf, Ursula Marschall, Alexander Katalinic, Fabian‐Simon Frielitz · 2022 · Cost Effectiveness and Resource Allocation
30. Cost Analysis of Pure Hypochlorous Acid Preserved Wound Cleanser versus Mafenide for the Irrigation of Burn Wounds
    Evelyn J. Rizzo, Peter J. Mallow, Aidan Noble, Kevin N Foster · 2024 · ClinicoEconomics and Outcomes Research
31. Cost-Effectiveness of Mineralocorticoid Receptor Antagonists in Ischemic and Nonischemic Heart Failure With Reduced Ejection Fraction: Perspective From a Universal Healthcare System
    Cristiane Koeche, Ana Cláudia Cavalcante Nogueira, Giselle Pinto da Silva Amaral, Adriana J. B. A. Guimarães, Yasmim Botelho Neiva, Ana Aparecida Adeodato de Souza, Marta Duran Fernandez, Luís Eduardo Paim Rohde, Andrei Carvalho Sposito, Luiz Sérgio Fernandes de Carvalho · 2025 · Value in Health Regional Issues
32. Multi-parameter health state assessment
    Miklós Kozlovszky · 2015 · IEEE International Work Conference on Bioinspired Intelligence (IWOBI)
33. Economic evaluation of HIV pre-exposure prophylaxis strategies: protocol for a methodological systematic review and quantitative synthesis
    Kednapa Thavorn, Howsikan Kugathasan, Darrell H. S. Tan · 2018 · Systematic Reviews
34. Alternative Conversion Methods for Transition Probabilities in State-Transition Models: Validity and Impact on Comparative Effectiveness and Cost-Effectiveness
    Beate Jahn, Christina Kurzthaler, Jagpreet Chhatwal, Elamin H. Elbasha, Annette Conrads‐Frank, Ursula Rochau, Gaby Sroczynski, Christoph Urach, Marvin Bundo, Niki Popper et al. · 2019 · Medical Decision Making
35. Gesundheitsökonomische Evaluation in der Gesundheitsförderung und Prävention
    Lena Hasemann, Juliane Andrea Düvel, Sebastian Gruhn · 2021 · Springer eBooks
36. Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
    Dean A. Regier, Brandon W. Chan, Sarah Costa et al. · 2022 · Cancers
37. Update on a Model to Minimize Population Health Loss in Times of Scarce Surgical Capacity During the COVID-19 Crisis and Beyond
    Benjamin Yaël Gravesteijn, Eline Krijkamp, Anouk M.I.A. van Alphen, Jan J.V. Busschbach, Geert Geleijnse, Isabel Retel Helmrich, Sophie M. Bruinsma, Céline van Lint, Ernest van Veen, Ewout Willem Steyerberg et al. · 2022 · Value in Health
38. Proportion of clinical holistic responders in patients with persistent spinal pain syndrome type II treated by subthreshold spinal cord stimulation compared to best medical treatment: a study protocol for a multicentric randomised controlled trial (TRADITION)
    Lisa Goudman, Koen D. Putman, Leen Van Doorslaer, Maxime Billot, Manuel Roulaud B, Philippe Rigoard, Bart Billet, Bart Bryon, Mark Plazier, Vincent Raymaekers et al. · 2023 · Trials
39. Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma
    Beranger Lueza, Anne Auperin, Charlotte Rigaud, Thomas G. Gross, Marta Pillon, Rafael F. Delgado, Anne Uyttebroeck, G.A. Amos Burke, József Zsíros, Monika Csóka et al. · 2023 · The European Journal of Health Economics
40. Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach
    Fanny Franchini, Victor Fedyashov, Maarten J. IJzerman, Koen Degeling · 2023 · Frontiers in Pharmacology
41. Improving resource allocation in the precision medicine Era: a simulation-based approach using R
    Mohamed Kamal, Mohamed Nagy, Omneya Hassanain · 2024 · Personalized Medicine
42. High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial)
    Catharina M.L. Zegers, Ans C. C. Swinnen, Cheryl Roumen, Aswin Louis Hoffmann, Esther G.C. Troost, Charlotte J.J. van Asch, Lloyd Brandts, Inge Compter, Edith M.T. Dieleman, Jeanette B. Dijkstra et al. · 2024 · Trials
43. Cost-effectiveness of applying high-sensitivity troponin I to a score for cardiovascular risk prediction in asymptomatic population
    Paul Jülicher, Nataliya Makarova, Francisco Ojeda, Isabella Giusepi, Annette Peters, Barbara Thorand, Giancarlo Cesana, Torben Jørgensen, Allan R Linneberg, Veikko V Salomaa et al. · 2024 · PLoS ONE
44. Rationale and design of a randomized clinical trial of integrated eHealth for PrEP and medications for opioid use disorders for women in the criminal legal system. The Athena study
    Jaimie P. Meyer, Stacey Brunson, Carolina R Price, Morgan Mulrain, Julie K. Nguyen, Frederick L. Altice, Tassos C. Kyriakides, Karen L. Cropsey, Ellen Eaton · 2025 · Addiction Science & Clinical Practice
45. How Secondary Interventions Reduce the Burden of Alcohol Consumption at Risk of Cirrhosis: A Public Health Decision‐Making Model
    Claire Delacôte, Line Carolle Ntandja Wandji, Alexandre Louvet, Pierre Bauvin, Philippe Mathurin, Sylvie Deuffic‐Burban · 2025 · Liver International
46. Cost-utility of a biofilm-disrupting gel versus standard of care in chronic wounds: a Markov microsimulation model based on a randomised controlled trial
    Marissa Janine Carter, Matthew F. Myntti · 2019 · Journal of Wound Care
47. Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years
    Soeren Mattke, Mark Hanson, Marc Bentele, David E. Kandzari · 2019 · Cardiovascular revascularization medicine
48. Análise de custo-efetividade de estratégias de rastreamento do câncer do colo do útero no Brasil
    Juliana Yukari Kodaira Viscondi · 2017 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
49. A Multidimensional Array Representation of State-Transition Model Dynamics
    Eline Krijkamp, Fernando Alarid‐Escudero, Eva A. Enns · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
50. hesim: Health Economic Simulation Modeling and Decision Analysis
    Devin Incerti, Jeroen Paul Jansen, Mark Clements · 2017
51. Microsimulation Modeling for Health Decision Sciences Using C++: A Tutorial
    Aku-Ville Lehtimäki, Janne A. Martikainen · 2025 · PharmacoEconomics
52. Evidence-based decision analysis guiding clinical guidelines for an organized population-based screening for colorectal cancer
    Beate Jahn, Gaby Sroczynski, Júlia Santamaria et al. · 2025 · Best Practice & Research Clinical Gastroenterology
53. Personalizing lung cancer screening recommendations for heterogeneous populations: a microsimulation study
    Joshua B. Rager, Pianpian Cao, Rodney A. Hayward · 2025 · JNCI Journal of the National Cancer Institute
54. Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force
    Sylwia Bujkiewicz, Oriana Ciani, Bart M. S. Heeg et al. · 2026 · Value in Health
55. The augmented representation of the cost-effectiveness acceptability curve for economic evaluation of health technology.
    Daiji Araki, Isao Kamae · 2015 · PubMed
56. Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective
    Roza Ismailovna Yagudina, A.Yu. Kulikov, V.G. Serpik · 2021 · ClinicoEconomics and Outcomes Research
57. Financial Burden of Transcatheter Aortic Valve Implantation
    Paola D’Errigo, Andrea Marcellusi, Fausto Biancari et al. · 2023 · The American Journal of Cardiology
58. Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting
    Andrew John Palmer, Ting Zhao, Bruce V. Taylor, Ingrid A.F. van der Mei, Julie A. Campbell · 2023 · Journal of Neurology Neurosurgery & Psychiatry
59. The use of social simulation modelling to understand adherence to diabetic retinopathy screening programs
    Andreia Penso Pereira, João Macêdo, Ana Afonso, Raul Manuel da Silva Laureano, Fernando Buarque de Lima Neto · 2024 · Scientific Reports
60. Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States
    Sean D. Sullivan, Shruti Chaturvedi, Preety Gautam · 2024 · Journal of Managed Care & Specialty Pharmacy
61. Analysis of the economically justifiable price of mepolizumab in adults with asthma in Colombia
    Jefferson Antonio Buendía, Diana Guerrero-Patino, Juan Antonio Buendia Sanchez · 2025 · Journal of Asthma
62. Cost-utility analysis of cultured human corneal endothelial cells for corneal edema secondary to endothelial dysfunction: a Monte Carlo simulation model.
    Tina Felfeli, Aswen Sriranganathan, C. Wedge, David M Naimark, Clara C. Chan · 2025 · Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie
63. The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care
    E. van der Meijde, Alfons J.M. van den Eertwegh, Sabine C. Linn · 2016 · Cancer Informatics
64. Estimating the risk of SARS-CoV-2 transmission to pediatric anesthesiologists: a microsimulation model
    Kazuyoshi Aoyama, Anna Heath, Alan Yang · 2020 · Canadian Journal of Anesthesia/Journal canadien d anesthésie
65. Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data
    Maria‐Theodora Pandi, Maria Koromina, Gerasimos Vonitsanos · 2022 · Pharmacological Research
66. Fiscal consequences of Alzheimer's disease and informal care provision in the UK: A “government perspective” microsimulation
    A.T. Paquete, Rui Martins, Nikolaos Kotsopoulos, Michael Urbich, Colin Green, Mark P. Connolly · 2022 · The Journal of the Economics of Ageing
67. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes
    William L. Herring, Ian Gopal Gould, Villum Wittrup-Jensen, Judith Ertle, Effie L. Kuti, Sorrel E Wolowacz · 2022 · Journal of Comparative Effectiveness Research
68. Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis
    J. Verbeek, K. van der Sluis, M. Vollebergh, J. V. van Sandick, W. V. van Harten, V. Retèl · 2023 · PharmacoEconomics - Open
69. A Markov Decision Process Approach to Estimate the Risk of Obesity Related Cancers
    Emine Yaylalı, Umut Karamustafa · 2019 · Lecture notes in management and industrial engineering
70. Improving Cycle Corrections in Discrete Time Markov Models: A Gaussian Quadrature Approach
    Tushar Srivastava, Mark Strong, Matt Stevenson · 2020 · medRxiv
71. RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Joaquim Rosado Cristino, Immanuel Tang, Caroline Ng · 2018 · Journal of Medical Economics
72. A scoping review of guidelines on reporting and assessing dynamic mathematical models of infectious diseases
    Madhav Chaturvedi, Madhav Chaturvedi, Antonia Bartz et al. · 2024 · medRxiv
73. Computer simulation of diabetic retinopathy screening adherence : Agent based model with fuzzy logic
    Andreia Penso Pereira, Raul Manuel da Silva Laureano, Fernando Buarque de Lima Neto, João Macêdo · 2021 · Iberian Conference on Information Systems and Technologies (CISTI)
74. A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment
    Enoch Yi‐Tung Chen, Paul William Dickman, Mark Clements · 2024 · PharmacoEconomics
75. Sensitivity of Cost-Effectiveness to Inclusion of Adverse Drug Events: A Scoping Review of Economic Models of Pharmacological Interventions for Diabetes, Diabetic Retinopathy, and Diabetic Macular Edema
    Mari Pesonen, Eila Kankaanpää · 2025 · ClinicoEconomics and Outcomes Research
76. Cost effectiveness analysis of expanding tuberculosis preventive therapy to household contacts aged 5–14 years in the Philippines
    Ghassan Ilaiwy, Jessica Keim‐Malpass, Romella Mendez Tuppal, Alexander F. Ritua, Flordeliza R. Bassiag, Tania A. Thomas · 2025 · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
77. Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia
    Arie Rahadi, Rizki Tsalatshita Khair Mahardya, Putri Listiani · 2025 · International Journal of Technology Assessment in Health Care
78. Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review
    Christopher G. Fawsitt, Elaine Gallagher, Alka Aggarwal Singh, Hannah Baker, Edward Kayongo, Howard H. Z. Thom, Noman Paracha · 2025 · PharmacoEconomics
79. A Cost–Utility Analysis of Surgical Site Infection Prevention: Broadening the Scope
    A. McFarland, S. Manoukian, Helen Mason, Jacqui S. Reilly · 2025 · Applied Health Economics and Health Policy
80. Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective
    Nadia Karim, David Michael Waterhouse, Simon Jones, Björn Stollenwerk · 2025 · Journal of Medical Economics
81. Concerns on methodological assumptions in the health economic evaluation of return-to-work interventions
    Afschin Gandjour · 2026 · Expert Review of Pharmacoeconomics & Outcomes Research
82. A conceptual health economic modelling framework to assess the cost-effectiveness of molecular target–driven treatment regimens in oncology
    Oskar Frisell, Eline Aas, Pia Sofie Henkel · 2026 · Acta Oncologica
83. Contemporary cost-effectiveness of endovascular versus open surgical repair of for elective infrarenal abdominal aortic aneurysms in the United Kingdom
    Vladica M. Veličković, Xiaoyang Du, Dawn M. Cooper, Maxim Souter, Julie Lyon, T.J. Cleveland, Simon Neequaye, Daniel Carradice · 2026 · Expert Review of Cardiovascular Therapy
84. Cost-Effectiveness of Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in India
    Saba Abidi, Denny John, Shridhar Dwivedi · 2026 · Value in Health Regional Issues
85. Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective
    Kun Shi‐van Wielink, Annegret Hella Dahlmann-Noor, Jieyi Li, Thom de Milliano, Frederic Ernst, Francesco Croci, Yuvraj Sharma, Yogesh Suresh Punekar · 2026 · PharmacoEconomics
86. Endovascular Treatment for Acute Ischemic Stroke: A Methodological Systematic Review of Health Economic Decision Modeling Studies
    Andreas Beisel, Hans‐Helmut König, Judith Dams · 2026 · PharmacoEconomics
87. Trust and Recognition
    James E. Stahl · 2014 · Medical Decision Making
88. Pharmacoeconomics
    Richard C. Dodel, Christopher Kruse, Annette Conrads‐Frank, Uwe Siebert · 2020 · Springer eBooks
89. Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling
    Felicitas Kühne, Ursula Rochau, Noman Paracha, Jennifer M. Yeh, Eduardo J. Sabate, Uwe Siebert · 2021 · Medical Decision Making
90. Long‐term benefits and harms of early colorectal cancer screening in German individuals with familial cancer risk
    Gaby Sroczynski, Lára R. Hallsson, Nikolai Mühlberger · 2023 · International Journal of Cancer
91. A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening
    Stuart James Wright, Ewan Gray, G Rogers, Anna Donten, Katherine Payne · 2024 · Applied Health Economics and Health Policy
92. A Comparison of International Modeling Methods for Evaluating Health Economics of Colorectal Cancer Screening: A Systematic Review
    Olivia Adair, Felicity Lamrock, James F. O’Mahony, Mark Lawler, Ethna McFerran · 2025 · Value in Health
93. Exploratory analysis of the economically justifiable price of reslizumab for asthma severe in Colombia
    Jefferson Antonio Buendía, Andrés Felipe Zuluaga · 2025 · BMC Public Health
94. Comparing the Costs Associated with Anxiolytic Agents for Reducing Distress in Children Undergoing Laceration Repair in the Emergency Department
    N. Tran, Yi-Shu Lin, Petros Pechlivanoglou · 2025 · Journal of the American College of Emergency Physicians Open
95. Health technology assessment: A bird′s eye view
    Praveen Kulkarni, Prashant Vishwanath · 2015 · International Journal of Health & Allied Sciences
96. Helseøkonomisk evaluering ved Nasjonalt kunnskapssenter for helsetjenesten
    Gunhild Hagen, Torbjørn Fosen Wisløff, Marianne Klemp · 2013 · Norsk Epidemiologi
97. Análisis coste-efectividad y coste-utilidad de apixaban frente a dabigatrán y rivaroxaban en el tratamiento y prevención secundaria del tromboembolismo venoso
    F. de Andrés-Nogales, Itziar Oyagüez, Luis Antonio Alvarez-Sala, Fernando Garcia-Bragado, Andrés Navarro‐Ruiz, Paloma González, Isabel Elías, Javier Soto · 2017 · PharmacoEconomics Spanish Research Articles
98. Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk
    Dominic Mitchell, Jason R. Guertin, Jacques LeLorier · 2018 · Molecular Diagnosis & Therapy
99. Markov model and meta-heuristics combined method for cost-effectiveness analysis
    Xiuxian Wang, Na Geng, Jianxin Qiu · 2019 · Flexible Services and Manufacturing Journal
100. Can We Determine the Optimal Cycle Length for Which Half-Cycle Correction Should Always Be Applied?
     Robert Drzał, Mark Parker, Robert Plisko · 2014 · Journal of Health Policy & Outcomes Research